Name: VA-PAB-DMEA-PNU159682
Brand: BOC Sciences
Rating: 5 (1 reviews)

Synonyms

4-((S)-2-((S)-2-amino-3-methylbutanamido)propanamido)benzyl (2-oxo-2-((2S,4S)-2,5,12-trihydroxy-7-methoxy-4-(((1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl)oxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)ethyl) ethane-1,2-diylbis(methylcarbamate); L-Alaninamide, L-valyl-N-[4-[11-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-4-[[(1S,3R,4aS,9S,9aR,10aS)-octahydro-9-methoxy-1-methyl-1H-pyrano[4',3':4,5]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy]-6,11-dioxo-2-naphthacenyl]-4,7-dimethyl-3,8,11-trioxo-2,9-dioxa-4,7-diazaundec-1-yl]phenyl]-; L-Valyl-N-(4-{4,7-dimethyl-3,8,11-trioxo-11-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-{[(1S,3R,4aS,9S,9aR,10aS)-9-methoxy-1-methyloctahydro-1H-pyrano[4',3':4,5][1,3]oxazolo[2,3-c][1,4]oxazin-3-yl]oxy}-6,11-dioxo-1,2,3,4,6,11-hexahydro-2-tetracenyl]-2,9-dioxa-4,7-diazaundec-1-yl}phenyl)-L-alaninamide

IUPAC Name

[2-oxo-2-[(2S,4S)-2,5,12-trihydroxy-7-methoxy-4-[[(2S,4R,6S,7S,9R,10S)-10-methoxy-6-methyl-5,8,11-trioxa-1-azatricyclo[7.4.0.02,7]tridecan-4-yl]oxy]-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]ethyl] N-[2-[[4-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]propanoyl]amino]phenyl]methoxycarbonyl-methylamino]ethyl]-N-methylcarbamate

Canonical SMILES

CC1C2C(CC(O1)OC3CC(CC4=C3C(=C5C(=C4O)C(=O)C6=C(C5=O)C(=CC=C6)OC)O)(C(=O)COC(=O)N(C)CCN(C)C(=O)OCC7=CC=C(C=C7)NC(=O)C(C)NC(=O)C(C(C)C)N)O)N8CCOC(C8O2)OC

InChI

InChI=1S/C53H66N6O18/c1-25(2)41(54)48(66)55-26(3)47(65)56-29-14-12-28(13-15-29)23-73-51(67)57(5)16-17-58(6)52(68)74-24-35(60)53(69)21-31-38(45(64)40-39(43(31)62)42(61)30-10-9-11-33(70-7)37(30)44(40)63)34(22-53)76-36-20-32-46(27(4)75-36)77-49-50(71-8)72-19-18-59(32)49/h9-15,25-27,32,34,36,41,46,49-50,62,64,69H,16-24,54H2,1-8H3,(H,55,66)(H,56,65)/t26-,27-,32-,34-,36-,41-,46+,49+,50-,53-/m0/s1

InChIKey

HOZDEOOIJBMFDN-IUQPRXLRSA-N

Density

1.46±0.1 g/cm3

Boiling Point

1156.1±65.0°C at 760 mmHg

VA-PAB-DMEA-PNU159682 is a potent ADC Cytotoxin with Linker, consisting of the PNU159682 payload attached via a cleavable VA-PAB ADC Linker with a DMEA functional group. This configuration ensures that the ADC payload remains stable during systemic circulation and is released specifically inside antigen-expressing tumor cells. As a defined ADC Cytotoxin, VA-PAB-DMEA-PNU159682 delivers the DNA-crosslinking PNU159682 payload efficiently, facilitating apoptosis through controlled intracellular release.

The cytotoxic mechanism of VA-PAB-DMEA-PNU159682 involves antibody-mediated binding to tumor-specific antigens, followed by internalization into target cells. Once inside lysosomes, the VA-PAB linker is cleaved by proteases, releasing PNU159682 directly in the cell. This selective release ensures that the ADC payload exerts its DNA-crosslinking activity specifically in tumor cells, achieving potent cytotoxic effects while minimizing systemic exposure. The DMEA functional group supports stable conjugation chemistry and predictable intracellular activation.

VA-PAB-DMEA-PNU159682 allows stable conjugation to monoclonal antibodies, producing homogeneous ADC Cytotoxins with Linker. The protease-sensitive VA-PAB linker ensures reliable intracellular payload release and consistent cytotoxic performance. Its chemical properties, including solubility, linker stability, and controlled cleavage, enable reproducible ADC assembly and precise delivery of PNU159682 in antigen-positive cells.

Applications of VA-PAB-DMEA-PNU159682 focus on its role as a defined ADC payload-linker combination for constructing homogeneous antibody-drug conjugates. The cleavable linker provides controlled intracellular release of PNU159682, producing consistent DNA alkylation and cytotoxicity. This reagent delivers potent, targeted effects in ADC Cytotoxins with Linker, supporting precise intracellular payload delivery in oncology-focused ADC development and research.

Catalog	Product Name	CAS
BADC-01417	MC-VC-PAB-DMEA-PNU159682	1178887-17-6
BADC-01357	PNU-159682 carboxylic acid	1204819-92-0
121487-74-9	trans-4-(Aminomethyl)cyclohexanecarboxamide	121487-74-9
BADC-01358	DMEA-PNU-159682	1799421-48-9
BADC-01424	NH2-VC-PAB-DMEA-PNU159682	2227350-96-9
BADC-01404	PNU159682-EDA	2255344-14-8
BADC-00737	MA-PEG4-VC-PAB-DMEA-PNU159682	2259318-52-8
BADC-00671	Mal-C2-Gly3-EDA-PNU-159682	2259318-53-9
BADC-00867	Mal-Phe-C4-VC-PAB-DMEA-PNU-159682	2259318-54-0
BADC-00762	DBCO-PEG4-VC-PAB-DMEA-PNU159682	2259318-56-2

What is VA-PAB-DMEA-PNU159682?

VA-PAB-DMEA-PNU159682 is a linker-payload conjugate integrating the potent PNU159682 cytotoxin with a valine-alanine-PAB-DMEA linker. It is designed for ADC applications to enable controlled intracellular release, enhancing target-specific cytotoxicity in preclinical and clinical research.

27/9/2017

Dear BOC Sciences, how does VA-PAB-DMEA-PNU159682 function in ADCs?

The valine-alanine-PAB-DMEA linker in VA-PAB-DMEA-PNU159682 is cleaved by intracellular proteases following ADC internalization, releasing PNU159682. This ensures targeted cytotoxicity and reduces systemic exposure, supporting precise evaluation of ADC efficacy.

5/12/2018

Dear BOC Sciences, what are the applications of VA-PAB-DMEA-PNU159682?

This conjugate is widely used in oncology ADC research, including solid tumors and hematologic malignancies. Its cleavable linker allows assessment of drug release kinetics, in vitro cytotoxicity, and in vivo efficacy, providing a reliable tool for ADC optimization.

21/6/2019

Dear Sir, could you please explain what makes VA-PAB-DMEA-PNU159682 suitable for ADC development?

VA-PAB-DMEA-PNU159682 combines a potent cytotoxin with a protease-sensitive linker, providing high plasma stability and selective intracellular release. This design enhances the therapeutic index and enables consistent ADC performance in experimental models.

8/3/2019

Dear BOC Sciences, can VA-PAB-DMEA-PNU159682 be adapted to different antibodies?

Yes, it supports conjugation to multiple monoclonal antibodies via cysteine or lysine residues. This flexibility enables researchers to design ADCs with specific targeting, adjustable drug-antibody ratios, and optimized pharmacokinetics.

23/9/2017

— Dr. Michael Adams, Senior Scientist (USA)

VA-PAB-DMEA-PNU159682 was key for achieving consistent cytotoxicity in our in vitro models.

21/6/2019

— Dr. Olivia Clark, ADC Chemist (UK)

This product's solubility and stability greatly simplified our ADC conjugation workflow.

23/9/2017

— Ms. Anna Rossi, Bioconjugation Specialist (Italy)

We sourced VA-PAB-DMEA-PNU159682 from BOC Sciences for exploratory ADC work. The compound showed excellent solubility and conjugation efficiency, making our experiments more efficient and productive.

8/3/2019

— Dr. Markus Schmidt, Head of CMC Development (Switzerland)

We were in urgent need of a kilogram-scale supply for our late-stage preclinical work. BOC Sciences came through with the VA-PAB-DMEA-PNU159682 on a tight deadline. The product met all our stringent specifications, and their regulatory support was invaluable. They are a reliable and responsive partner in this field.

27/9/2017

— Dr. Christoph Mueller, Head of Process Development (Germany)

We faced a tight deadline for a large-scale project. BOC Sciences provided VA-PAB-DMEA-PNU159682 ahead of schedule, meeting our strict quality standards.

— Mr. Daniel Perez, Molecular Pharmacologist (Spain)

VA-PAB-DMEA-PNU159682 from BOC Sciences was an important part of our exploratory ADC design. The linker-toxin construct displayed high solubility and strong reproducibility across multiple trials.

5/12/2018